Clinical Trial Update: EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma [Phase 3]

View source ↗

Summary

Phase 3 trial EF-41/KEYNOTE D58 evaluating Optune with temozolomide and pembrolizumab for newly diagnosed glioblastoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• OPTUNE
• Pembrolizumab (pembrolizumab)
• Temozolomide (Temozolomide)

Snippet

Sponsor: NovoCure GmbH | Conditions: Glioblastoma | Phase 3 | Status: RECRUITING